MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Companies: Acquiring (M&A)
Crown Laboratories, Inc.*
Finance & Acquisition: Crown Laboratories
Revance Therapeutics, Inc (NASDAQ:RVNC)*
Organization & Developments: Revance
Parents
Revance Therapeutics, Inc (NASDAQ:RVNC)*
Children
*Has developed the proprietary TransMTS™ platform technology which enables local, targeted delivery of large macromolecules across skin
*Manufactures family of purified, well characterized botulinum toxin molecules that could potentially be used for migraine, rhinitis and other disease states for which botulinum toxin is an appropriate treatment
*ReVance Therapeutics-Company Profile
*Revance Therapeutics, Inc. (NASDAQ: RVNC) is a commercial stage biotechnology company focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection
2016: Revance Therapeutics (NASDAQ:RVNC) whose stock fell over 20% Monday after disclosing its lead product candidate DaxibotulinumtoxinA Topical Gel (RT001) flunked a Phase 3 study, REALISE 1, in patients with moderate-to-severe lateral canthal lines (cro
2017: Biotech Forum Daily Digest: Spotlight feature - Revance Therapeutics (NASDAQ:RVNC) _Acorda Therapeutics' Bleak Future, Invitae's Roll Continues
2017: Revance Therapeutics: Sakura Success Should Worry Allergan - Revance Therapeutics, Inc. (NASDAQ:RVNC)
2020: Biotech Analysis Central Preview Series: Revance Therapeutics
2022: Revance Therapeutics: FDA Approval Of Daxxify Only One Part Of The Journey_ seekingalpha.com
2024: Revance Therapeutics' SWOT analysis: tender offer shakes up specialty pharma stock
2024: Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain
2025: Revance Therapeutics: The Takeover Saga Continues As Teoxane Enters The Fray
Jumps
*Key People: Revance
Finance & Acquisitions: Revance